Physician profile
Robert L Orme
NPI 1174635403
$4,197.65
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $584 · 2021: $1,016 · 2022: $721 · 2023: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.96 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $547.88 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $497.99 | 2019-2023 | Absorica Ld, Winlevi, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $385.69 | 2019-2022 | |
| Amgen INC. | $365.95 | 2019-2023 | Otezla |
| Pfizer INC. | $341.08 | 2020-2023 | |
| Galderma Laboratories, L.P. | $303.70 | 2019-2021 | |
| Ucb, INC. | $227.70 | 2021-2022 | |
| Incyte Corporation | $201.23 | 2022-2023 | Opzelura |
| Janssen Biotech, INC. | $123.02 | 2019-2021 | |
| Dermira, INC. | $121.08 | 2019 | |
| Lilly USA, LLC | $83.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $80.82 | 2019-2021 | |
| Genzyme Corporation | $73.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $60.57 | 2023 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $34.29 | 2019 | |
| Boston Scientific Corporation | $21.23 | 2022 | |
| Leo Pharma INC. | $20.62 | 2023 | Adbry |
| Dermavant Sciences, INC. | $20.59 | 2023 | Vtama |
| Biofrontera INC. | $17.42 | 2022 | |
| Mylan Pharmaceuticals INC. | $15.80 | 2019 | |
| Hologic Sales and Service, LLC | $15.48 | 2023 | Myosure Tissue Removal Device |
| Prugen, INC. Pharmaceuticals | $4.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Orme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.